Marcus L. Williams, MD

Cardiac Associates of North Jersey, P.A.
Phone: 201-788-3886
Fax: 201-612-3063
Web site:


a. Undergraduate:

1973-1977 Yale University: B.A.

b. Graduate and Professional:

1978-1982 George Washington University:
M.D. with Honors


a. Internship and Residencies:

1982-1983 Internship, University of North Carolina

b. Residence Fellowships:

1983-1984 Junior Resident, University of North Carolina
1984-1985 Senior Resident, University of North Carolina

c. Research Fellowship:

1985-1986 Research Fellow in Cardiology,
University of North Carolina

1986-1988 Clinical Fellow in Cardiology,
University of North Carolina



New Jersey Medical Licenses 65036
New York License 203986
North Carolina License 27343


a. Specialty Board: Internal Medicine Certified

b. Sub-Specialty Board: Cardiology Certified

c. Sub-Specialty Board: Nuclear Cardiology Certified

d. Sub-specialty Board: Cardiac CT Angiogram

e. Sub-specialty Board: Echocardiogram


NJ DEA BW4660052


1986 – 1989 Clinical Instructor in Cardiology
University of North Carolina (UNC)

1990 – 1996 Assistant Professor of Medicine
University of North Carolina (UNC)

1990 – 1996 Education Coordinator for Cardiology in
Patient Service,
University of North Carolina (UNC)

1997- 2010 Assistant Professor of Medicine
New Jersey Medical School (UMDNJ)

1996 – 2011 Chief of Cardiology
East Orange VA


1989 – 1994 Associate Director of the Cardiology in Patient Service North Carolina Memorial Hospital (NCMH)

1994 – 1996 Director of the Cardiology in Patient Service
North Carolina Memorial Hospital (NCMH)

1989 – 1996 Coordinator for CQI/Quality Assurance for Cardiology

1996 – 2010 Clinical Assistant Professor of Medicine at UMDNJ

1996 – 2010 Staff Cardiologist at Bergen Regional Hospital Center

2001 – Present Staff Cardiologist at Chilton Hospital

2001 – Present Staff Cardiologist at Valley Hospital Center, Ridgewood, New Jersey



Special Contribution Award (from VA Of New Jersey Healthcare System)
Howard F. Kane Obsterical Society: Active Fellow
Henry Kaiser Award: Merit Scholar
Alpha Omega Alpha Honor Society
Junior Faculty Development Award
Harvey Nussbuam Award: American Heart Association


Advisory Board for Medical Review of North Carolina
September 1, 1994 – June 1, 1996

Board of Director BB & T Bank, Chapel Hill NC
1995 to 1996

Board of Director
Triangle Church; President

Association of Black Cardiologist
2004 to Present

Past Board of Director and President
Association of Black Cardiologist

American Heart Association
2004 to Present

Board of Director and Past President local North Jersey Chapter
American Heart Association
2004 to 2008

Board of Directors AHA Founders Affilliate
American Heart Association
2010 to Present


a. Medical School:

1995 – 1996 Faculty Council Member

1994 – 1996 Deans Committe on Recruitment
Minorities to Medical School

1994 – 1996 Advisory Zollicof Lecture

b. Hospital:

1992 – 1995 CCU Renovation Committee
1990 – 1996 CQI Teams: Chest Pain Team, Cath to CABG Team
Coordinator for major renovations and expansion on cardiology
CQI Team: CHF Pathway, Medicaring Project
Clinical Guideline Development Committee
Establish CHF Clinic
1999 Establish Lipid Secondary Prevention Clinic

c. Department:

1994 – 1996 Heart Center Committee
1990 – 1996 Clinical Core Group
1990 – 1992 Recruitinent Committee for
Electrophysiology Directorship
1993 – 1995 Recruitment Committee for Medical
Cardiac Transplant Director
1991 – 1996 Myocardial Infarction and Ischemia
Thrombolysis Group
1989 – 1996 Basic Electrophysiology Research Group
1994 – 1996 Research Training in Experimental
Cardiology Member
Past Chair Person for CPR Committee at VANJHCS
Past Present Chair Person for ACLS ambulance transport
Past UMDNJ: Interviewer applying house staff

d. National Region:

Past Council for Hypertension – AHA
Past Council for Clinical Cardiology
Past Council for Thrombolysis
Past Reviewer for the Peer Review Journal Circulation

Major Programs and Educational Conferences

Hope Worldwide, Inc. Co-lead a program that looked the practice of medicine in Jamaica as it pertained to diabetes, hypertension and asthma. Recruited speakers,
helped locate and established the site and set up the program.
Speaker. Program sponsored by UNC at Chapel Hill.

2007 CVD in the Third World and Liberia: CME program focused on hypertension and diabetes. Sponsored by UMDNJ.


1996 American Medical Association
1991 – 1993 American Heart Association
Vice President and President of local North Carolina Chapter
1989 – Present American College of Physicians
North Carolina Medical Society
1997 – Present Fellow of American College of Cardiology
1996 – Present North Jersey Medical Society
1996 – Present American Black Cardiologist Association
National Board Member
Past President American Heart Association of local New Jersey Chapter
Past Vice President American Heart Association of local New Jersey Chapter


– Outcomes Research in Ischemic Heart Disease
– Clinical Trials in Acute Ischemic Syndrome
– Mechanisms of Sudden Death, Basic EP Lab.


a. Principle Investigator or P1 of Sub-Contract:

– American Heart Association 1 Year Grant 1992 $20,000.00

– NHLB- Minority Research Training Grant $98,250.00

– CQI Hospital Grant 1 Year Grant 1992 $31,000.00

– Junior Faculty Award 1996 $3,200.00

– Pfizer unrestricted Grant $78.000.00
– Outcomes Research in Acute Coronary Syndromes no funding Looking at the efficacy of implementing specific tools to improve adherence to guidelines and pathways and assessing this impact on clinical outcomes.

b. Co-Investigator:

– Effect of calcium antagonist on extracellular ionic changes in schemic porcine myocardium. American Heart Association $25,000 1989-1990.

– Activase Registry: A Genentech-sponsored registry of all myocardinal infarction patients. Genentech $6,000.00

– Effects of ATP-dependent K+ channel blockers and
activators on ionic and electrical changes in the
ischemic porcine myocardium. American Heart Association

– Thrombosis in Myocardial Infarction Ill-B (TIMI Ill-B):
Examines the role of t-PA and aggressive versus conservative management in unstable angina and non-Q wave myocardial infarction. NIH funded $32,000.00.

– Thrombolysis in Myocardial Infarction Ill-B Registry: A Natural History Study Looking at Outcome of minorities and Women with Unstable Angina or non-Q wave Myocardial Infarction.

– Thrombolysis in Myocardial Infarction VI ((TIMI VI) I VI): Comparison of Recombinant Hirudin and Heparin when Given in Conjunction with Streptokinase to Patients with Acute Transmural Myocardial Infarction. NIH $30,000.00 1993-1994.

– MK 852: A safety study on use of MK 852, a platelet inhibitor, in patients with unstable angina. A comparison of MK 852 to heparin. Merck Pharmaceutical $20,000.00 1993

– MK 3 83: Phase III Trail on platelet inhibition in patients wit unstable angina. Merck Pharmaceutical $64,000.00 1994-1996.

– Designed and evaluated a critical pathway for the management of complicated and uncomplicated MI. Hospital $30,000.00 1992- 1996.

– Essence Trail: Phase II Trail use of low molecular weight Heparin in unstable angina. CIBA Pharmaceutical $50,000.00 1995-1996.

– Used CQI techniques to improve the quality of service on the Cardiology consult service. In a non funded Project. Hospital 1991-1996.

– TIMI 9A/9B – Phase III Trail use of Hirudin as adjunctive therapy in patients receiving Thromobolytic Agents for Acute Myocardial Infarction. CIBA $30,000.00

OPUS TIMI 16 – Phase III Trial of Orifiban, a 2b/3a Platelet Receptor Inhibitor, in Acute Coronary Syndromes. Searle $44,000.00

Losartan Efficacy in Mild Hypertension in Afro-Americans Trial. This is hypertension trial looking Losartan effects in Afro-Americans. Merck $12,000.00
Tamsulosin on Urine Flow Parameters in Patients with Clinical BPH. There is an ECG evaluation component to the protocol. Merck sponsored

TACTICS- Phase III trial looking at best treatment strategies: Invasive versus conservative in patients who receive aggressive medical treatment, including Aggrastat. Merck $30,000.00

BRAVO Trial- Examine the efficacy of oral 2B/3A platelet inhibitor, Lotrafiban in reducing cardiac events in high risk cardiac patients SmithKline and Beecham $40,000.00

A to Z Trial- This will be a two part trial. It is a Phase 4 trial. The A trial involves looking at the safety of combining 
Aggrastat and Lovenox. The second part looks at the outpatient titration of Zocor on lipid profile in these patients. Merck

SPORTIF V- Phase 3 trial looking at the safety and efficacy and safety of an oral direct thrombin inhibitor H376/95 compared to dose adjusted warfarin for the prevention of stroke and systemic embolic events in patients with atrial fibrillation. AstraZeneca

PROVE IT- This is a Phase 4 trial looking at head to head comparison of pravachol to atorvastatin. Second arm of this study looks at the long term use of an antibiotic to treat Chlamydia Pneumonia. This study will look at rate the primary end points of cardiovascular and the secondary end points of lipids, inflammatory markers, and ant chlamydial antibodies. TIMI 22

Achievement of LDL-Cholesterol Level Goal by Simvastatin- Co-Principal Investigator in this dose titration curve looking at compliance rate with NCEP recommendation versus mean dose of Simvastatin. VANJHCS and Merck $90,000.00

Comparison Study of Atorvastatin versus Simvastatin in NCEP compliance rate with high risk cardiovascular and diabetic patients. $75,000.00


The Affirm Trial looking at outcomes in patients with atrial
Fibrillation. A comparison of Rhythmol with other therapy outcomes. Year 2005.

Second atrial fibrillation trial: Comparison of Coumadin to Debigatran in anticoagulation of high risk atrial fibrillation patients. Year 2005.

The AFFIRM Trial: National Atrial Fibrillation Registry

The IMPROVE IT Trial: Double blinded comparison of Vytorin and Zocor on cardiovascular events in acute coronary syndromes

The RELY Trial: Comparison of Dabigatran against Coumadin in reducing strokes in chronic atrial fibrillation patients who are at high risk for stroke. Year 2006 to 2015.

The Orbital Trial: Atrial Fibrillation Registry


a. Taught students, staff and peers during Medicine and Cardiology Grand Rounds. Informal lectures for medical students, house staff and fellows. Supervised and precepted medical students in the basic research laboratory. Coordinator of the core curriculum for the Cardiology Section for third year medical students.
Every Thursday 1990 – 1996.

b. Organized and taught “The Management of Acute Coronary Patients in the CCU” for referring physicians. 50 hour CME course. CME Accreditation 1994 – 1995.

c. Past Director of Minority Student Research Training Fellowship. NIH funded program where six minority students participated in a 12 week laboratory experience with course curriculum. 1992 – 1996.


1989 – 1996.

Clinical Patient Care, Treadmill testing, EKG, Echocardiogram. 25% of hospital time spent on CQI and Quality Assurance. 1989-1996

Clinical inpatient and Outpatient cardiology
Echocardiography- both Trans esophageal and
Transthoracic, Dobutamine Echo
Cardiac Catheterizations both left and right heart
Stress Testing: treadmill, nuclear and echocardiography
ECG and Holter interpretation


1994 – 1996 Director of Inpatient Cardiology and the CCU.

1989 – 1994 Associate Director of Inpatient Cardiology
and the CCU.

19. PRIVATE PRACTICE: Cardiac Associates of North Jersey 2001 – 2016

20. SOLO PRACTICE: December 2016.



Mazonson P, Williams M, et al. Myxedema coma during long-term amiodarone therapy. Am J. Med 1984;77.

Williams ML, Woelfel A, Cascio W, Simpson RJ Jr., Gettes LS, Foster JR. Amiodarone during prolonged resuscitation from cardiac arrest.
Ann Int Med 1989;ll0:839-862.

Stone P, Kleimon N, Kronenberg M, Willeson J, Williams M,
Prior MJ, Thompson B, Braunbald T. Effect of Gender, Race,
Age on the Natural history of unstable Angina and Non Q-Wave
MI: The T3 Registry. American College of Cardiology, JACC,
1993 Vol 21 No. 2 (Suppl A) P453A.

Gunnarsson PS, Sawyer WT, Montague D, Williams ML, Dupuis
RE, Caiola SM. Appropriate use of heparin: Empiric versus nomogram
based dosing.
Archives of Intern Med 1994;155:526-32.

The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 1994;89:1545- 1556.

Treatment of Myocardial Infarction in the United States
(1990 to 1993). Circulation 1994;90:2103-2114.

Antman E, for the TIMI 9A investigators. Hirudin in Acute
Myocardial Infarction, Safety Report From the Thromobolysis
and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A
Trail. Circulation 1994;90:1624-1630

Williams ML, O’Meara JJ, Tate DA, Simpson RJ. Acute
Myocardial infarction, A Guide for North Carolina Doctors.
NCMJ August, 1995, Volume 56, Number 8.

Maynard C. Weaver D. Lambrew C, Bowlby L, Rogers W,
Rubison M, for the participants in the National Registry of
Myocardial infarction. Factors Influencing the Time to
Administration of Thromobolytic Therapy With Recombinant
Tissue Plasminogen Activator (Data from the National Registry
of Myocardial infarction). The American Journal of
Cardiology Volume 76, September, 1995.

Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N,
Rogers WJ, for the Participants in the National Registry of
Myocardinal infarction. Recent Age-Related Trends in the Use
of Thromobolytic Therapy in Patients Who have Had Acute
Myocardial infarction. Ann Intern Med 1996;124:283-291.

Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, Pearce DJ, Diber DJ, Kells C, Feldman T, Williams M, Gibson RS, Kronenberge MW, Ganz LI, Anderson HV, Braunwald E The Electrocardiogram Predicts One-Year Outcome of Patients with Unstable Angina an Non-Q Wave Myocardial Infarction: Results of the TIMI III Registry ECG Ancillary Study. J Am Coll Cardiol 1997;30:133-40

Williams ML, Hill G, Jackson MJ. Acute Myocardial Infarction at a University Hospital: Effect of Race on Short-term Mortality. JAAMP 2000;11:1-4.

OPUS-TIMI 16 Investigators. Oral Glycoprotein IIb/IIIa Inhibition with Orbofiban in Patients with unstable coronary syndromes (OPUS-TIMI 16) Trial. Circulation 2000;102:149-156.

TACTICS-TIMI 18 Investigators et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein 2b/3a inhibitor tirofiban. N Eng J Med 2001;344:1879-1887.


Williams ML, Tate DA. Acute Interventions in Myocardial Infarction. Emergency Medicine, A Comprehensive Study Guide,
4th Edition, 1995.


Williams ML, Gettes LS, Johnson T, Fleet WF, Cascio W.
Dose-dependent glibenclamide reduction in extracellular
potassium rise and activation delay in the in-situ pig heart.
Circulation (Supp 4) 1991;II-551.

Theroux P, Kleiman N, Shah PK, Williams M, gill J,
Rodriguez S, Niederman A, Broderick G, Josephson R,
Deschenes N, Kitzpatrick V and Sax F. (The MK-852
Investigators.) A Double-Blind, Heparin-Controlled Study of
MK-852 in Unstable Angina. American Heart Association. 66th Scientific Sessions (Abstract), 1993.

Lee LV, McCabe CH, Antman EM, Koch M. Wilensky R, Stringer K, Hochman J, Mueller HS, Henry TD, Kleiman N, Steingart RM, Wasserman H, Losordo D, Ludbrook P, Doorey A, Rodriguez S, Kennedy P, Rogers WJ, Williams ML, Smitherman TC, Gibson RS, Willerson JT, Edwards S,
Henis M, Braunwald E, for the TIMI 6 Investigators, Harvard Medical School, Brigham & Women’s Hospital Boston, MA. Initial experience with Hirudin and streptokinase in acute myocardial infarction:
Results of the TIMI 6 Trail. American College of Cardiology 43rd Annual Scientific Session (Abstract), 1994.

Williams DO, Sharaf BL, Braunwald E, Thompson B, Knatterud GL, Buller CE, TIMI 3 Investigators. Percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial ischemia: The TIMI-3 experience. American Heart Association 67th Scientific Sessions (Abstract), 1994.

Stone P, Kleiman N, Kronenberg M, Anderson HV, Williams M,
Knatterud G, Thompson B, Braunwald E. The influence of race and age on the management and outcome of patients with unstable angina and non-Q-wave MI. TIMI III Registry. American Heart Association 67th Scientific Sessions (Abstract), 1994.

Anderson HV, Cannon C, Williams D, Stone P, McCabe C,
Knatterud G, Thompson B, Willerson J, Braunwald E. One-year results of the TIMI-IIIB clinical trail. American Heart Association 67th Scientific Sessions (Abstract), 1994.

Cannon CP, Stone PH, Rogers WJ, McCabe C, Schactman M,
Diver DJ, Kells CM, Williams M, Feldman T, Kronenberg M,
Pearce DJ, Gibson RS, ECG as a Predictor of Outcome in Acute
Coronary Syndromes. Results of the TIMI III Registry ECG
Ancillary Study. American College of Cardiology 43rd Annual
Scientific Session (Abstract), 1994.

Williams ML, Engle C, Cascio W, Gettes L, Experimental
Cardiology Group, University of North Carolina, Chapel Hill,
NC. Lack of Effect of Pinacidil on Extra Cellular K+
Accumulation During the Early Phase of Acute No Flow Ishemia
in the In-Situ Pig. Journal of the Association of Academic
Minority Physicians Volume 4, Number 4, 1993.

Williams ML, Hill G, Jackson M, Griggs TR. Racial
Differences in Short Term Outcomes for Acute Myocardial
Infarction. Circulation (Supp 8), 1995; 1-437-2087.

Williams ML, Ademokekum J, Jackson M, Hill G The Impact of a Chest Pain Unit Without Walls. Fourth National Gongress of Chest Pain Centers in
Emergency Departments. Heart Attack: The Public Health Challenge for
The New Millinnium. 2000:47.

Youssef M, Willliams ML, Morris MT, Ahmad U, Li W, Ertel N. Racial differences in compliance to NCEP-II recommendations for secondary preventin at a veteran affair medical center. Ethnicity & Disease 2001;11:339.

Williams ML, Hill G, Jackson M. Comparison of the severity of coronary artery disease in acute myocardial infarction by race. Ethnicity & Disease 2001;11:339.

Williams ML, Hill G, Jackson M. The Impact of an Acute Myocardial Infarction Pathway on Racial Outcomes at a University Hospital.
Ethnicity & Disease 2006, scheduled for print.


Williams ML, Lawton JJ, Griggs TR. Dilemmas in the
Management of a Patient with Peripheral Vascular Disease.
JCOM July/August 1995.

Poster Presentations

Williams ML, Cardiology and EOVA. The Help Project. This looked at the results of several interventions to improve outcome and satisfaction for end of life CHF patients. Presented: VA National Leadership Conference on Pain Management and End of Life Care. November 2-5, 1999.